DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sutent (Sunitinib Malate) - Published Studies

 
 



Sutent Related Published Studies

Well-designed clinical trials related to Sutent (Sunitinib)

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. [2013]

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). [2013]

Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. [2012]

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2011.12]

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. [2011.07]

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. [2011.07]

Phase II study of sunitinib malate in patients with recurrent high-grade glioma. [2011.07]

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. [2011.04]

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. [2011.02.10]

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. [2010.12]

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2010.08.10]

Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. [2010.08]

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. [2010.05.25]

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. [2010.05]

Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. [2010.03]

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. [2010.02.16]

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. [2009.11]

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. [2009.09.01]

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. [2009.08.01]

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. [2009.07]

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. [2009.01.20]

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. [2008.01.15]

Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. [2007.12]

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. [2007.07]

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. [2007.03.01]

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. [2007.01.11]

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. [2006.10.14]

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. [2006.03]

Well-designed clinical trials possibly related to Sutent (Sunitinib)

Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. [2015]

Regorafenib in gastrointestinal stromal tumors. [2014]

New treatment strategies in advanced neuroendocrine tumours. [2011.10.07]

Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. [2011.06]

MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. [2011.06]

Targeted therapies for thyroid tumors. [2011.04]

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. [2011.01]

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. [2011]

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. [2011]

Pazopanib in renal cell carcinoma. [2010.12.15]

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. [2010.11.15]

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double Blind, Placebo Controlled Phase III Study. [2010.09.29]

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. [2010.09.15]

Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. [2010.01]

Pazopanib in renal cell carcinoma. [2010]

Everolimus: in advanced renal cell carcinoma. [2009.10.22]

Role of everolimus in the treatment of renal cell carcinoma. [2009.10]

Everolimus: in advanced renal cell carcinoma. [2009]

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. [2008.08.09]

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. [2008.01.15]

Other research related to Sutent (Sunitinib)

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. [2014]

Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. [2014]

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. [2014]

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. [2013]

A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer. [2013]

Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. [2013]

Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. [2013]

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. [2013]

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. [2012]

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. [2012]

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. [2012]

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. [2012]

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. [2012]

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. [2012]

Sunitinib for advanced pancreatic neuroendocrine tumors. [2011.12]

Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey. [2011.12]

RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. [2011.11.21]

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. [2011.11.11]

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. [2011.11]

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. [2011.10.06]

Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. [2011.10.01]

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. [2011.09.06]

Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. [2011.09]

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. [2011.08.25]

Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report. [2011.05]

Sunitinib and other targeted therapies for renal cell carcinoma. [2011]

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2011]

Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. [2011]

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. [2010.09.07]

Sunitinib for the treatment of metastatic renal cell carcinoma. [2010.09.01]

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. [2010.09]

Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. [2010.09]

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. [2010.08.14]

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. [2010.08]

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. [2010.08]

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. [2010.07.25]

Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma. [2010.05]

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. [2010]

A phase I study of sunitinib plus bevacizumab in advanced solid tumors. [2009.10.01]

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. [2009.10]

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. [2009.09.20]

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. [2009.09.10]

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. [2009.09.03]

Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. [2009.08.12]

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. [2009.08]

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. [2009.08]

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. [2009.07.24]

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. [2009.07.21]

Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. [2009.07.15]

Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. [2009.07]

Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. [2009.07]

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. [2009.06.23]

Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. [2009.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017